# A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

Study · id `cardio:ct-nct01970059` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01970059](<https://clinicaltrials.gov/study/NCT01970059>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01970059

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 302 participants.

## Technical summary

Registry record NCT01970059. Randomized; double masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2013-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 302 participants (planned count; ClinicalTrials.gov record NCT01970059, source copy `cardio:ctgov-nct01970059-2013-10-25`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01970059, source copy `cardio:ctgov-nct01970059-2013-10-25`, retrieved 2026-10-26)
- Primary completion: 2013-10 (anticipated) (ClinicalTrials.gov record NCT01970059, source copy `cardio:ctgov-nct01970059-2013-10-25`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: China (ClinicalTrials.gov record NCT01970059, source copy `cardio:ctgov-nct01970059-2013-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01970059-2013-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
- Condition: Hypertension
- Intervention (Drug): Extended-Release Carvedilol Sulfate
- Intervention (Drug): Sustained-release Metoprolol Succinate
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 82039ee2b1a3329c7e421f5b8bb19d8e65895659254bbc4e1ea1e5acfcb66b85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
